THE RESEARCH OF DR. JACK ARBISER

The  Arbiser lab has made major strides in melanoma in 2015. Honokiol, a  small natural product from the Magnolia plant, was found to cause  mitochondrial normalization by the Arbiser lab and other labs. Most  melanomas contain Braf, and abnormal mitochondria are required for Braf  to transform melanoma. The Arbiser lab has developed and patented new  derivatives of honokiol. These derivatives normalize the mitochondria in  aggressive melanoma cells and inhibit the growth of melanoma cells  which are resistant to vemurafenib, the major drug used for melanoma.  This paper has been submitted to Oncotarget. In addition, Dr Arbiser has  collaborated with Dr Jing Chen to find

Read about recent studies by Dr. Jack Arbiser

Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo Feburary 9th, 2016

Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling

PHIPing out: a genetic basis for tumor ulceration

Clinical Cancer Research September 14, 2008

Inducing apoptosis of cancer cells using small-molecule plant compounds that bind to GRP78

Please make your donation today to continue this much needed research